973PD - Dose-Dense Weekly Paclitaxel and Carboplatin Is More Cost-Effective Than Bevacizumab Plus Triweekly Paclitaxel and Carboplatin for the Primary Treatment of Advanced Ovarian Cancer

Abstract

ABSTRACT Purpose To determine whether dose-dense weekly paclitaxel and carboplatin (ddPC) is cost effective compared to bevacizumab plus triweekly paclitaxel and carboplatin (PCB) for the primary treatment of advanced ovarian cancer. Methods A cost-effectiveness analysis compared three treatments: 6 cycles of paclitaxel and carboplatin (PC), 6 cycles of PC plus bevacizumab followed by 12 cycles of maintenance bevacizumab (PCB), and 6 cycles of dose-dense weekly paclitaxel and carboplatin (ddPC). Data were taken from reported results of ICON7 (PC and PCB) and JGOG3016 (ddPC). Actual and estimated costs of treatment plus costs of complications were established for each regimen. Progression-free survival and rates of complications were estimated based on the results of clinical trials. Incremental cost-effective ratios (ICER) per progression-free life-year saved (PFLYS) were estimated. Results The ICER for ddPC was $5,000 per PFLYS compared to PC. For PCB compared to PC, the ICER was $285,000 per PFLYS. When compared simultaneously, PCB was more costly and less effective than ddPC. Conclusions In this model, dose-dense weekly paclitaxel and carboplatin is more cost effective than PCB for the treatment of advanced ovarian cancer. Disclosure All authors have declared no conflicts of interest.